

Stabilis



Human albumin



Noms commerciaux

| | |
|-------------------------|---|
| Acebumin | Pérou |
| Albital | Italie |
| Albuman | Grèce, Islande, Turquie |
| Albumed | Inde |
| Albumex | Australie, Nouvelle Zélande |
| Albumina humana | Brésil, Chili, Colombie, Equateur, Espagne, Mexique, Pérou, Portugal, Vénézuéla |
| Albuminativ | Irlande, Malaisie, Norvège, Suède |
| Albumine humaine Baxter | France |
| Albunorm 20% | France |
| Alburex 20% | France |
| Vialebex 20% | France |



Stabilité en mélange

| | | 250 mg/ml | 25°C | | Furosemide : 1.07 mg/ml | 48 | | 3490 |
|--|--|-----------|------|--|-------------------------|----|--|------|
| | | 250 mg/ml | 4°C | | Furosemide : 1.07 mg/ml | 14 | | 3490 |



Compatibilités

| | Human albumin : 250 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml | 3824 |
|--|--|------|
| | Human albumin : 100 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml | 3976 |
| | Human albumin : 100 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml | 3976 |
| | Human albumin : 250 mg/ml Caffeine : 10 mg/ml | 3964 |
| | Human albumin : 250 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml | 3828 |
| | Human albumin : 250 mg/ml Dexmedetomidine : 100 µg/ml | 4389 |

| | | | | |
|--|--|--|----|------|
| | | Human albumin : 250 mg/ml Esmolol hydrochloride : 10 mg/ml | | 3879 |
| | | Human albumin : 200 mg/ml | | 3948 |
| | | Human albumin : 250 mg/ml Fosfomicin : 30 mg/ml | | 4055 |
| | | Human albumin : 250 mg/ml | RL | 4603 |
| | | Human albumin : 250 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL | | 4528 |
| | | Human albumin : 200 mg/ml Defibrotide : 8 mg/ml | | 3728 |
| | | Human albumin : 250 mg/ml Diltiazem hydrochloride : 5 mg/ml | | 198 |
| | | Human albumin : 50 mg/ml Diltiazem hydrochloride : 5 mg/ml | | 198 |
| | | Human albumin : 250 mg/ml Eravacycline : 0,6 mg/ml | | 4434 |
| | | Human albumin : 250 mg/ml Hydrocortisone sodium succinate : 1 mg/ml | | 4465 |
| | | Human albumin : 50 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml | | 4433 |
| | | Human albumin : 250 mg/ml Isavuconazonium sulfate : 1.5 mg/ml | | 3829 |
| | | Human albumin : 250 mg/ml Labetalol hydrochloride : 5 mg/ml | | 3879 |
| | | Human albumin : 200 mg/ml Lorazepam : 0.33 mg/ml | | 186 |
| | | Human albumin : 250 mg/ml Metoprolol tartrate : 0.4 mg/ml | | 3879 |
| | | Human albumin : 250 mg/ml Micafungin : 1.5 mg/ml | | 2108 |
| | | Human albumin : 200 mg/ml Midazolam hydrochloride : 5 mg/ml | | 186 |
| | | Human albumin : 250 mg/ml Paracetamol : 10 mg/ml | | 4742 |
| | | Human albumin : 250 mg/ml Plazomicin sulfate : 24 mg/ml | | 4145 |
| | | Human albumin : 250 mg/ml Sulbactam/durlobactam : 15/15 mg/ml | | 4801 |
| | | Human albumin : 250 mg/ml Tedizolid phosphate : 0.8 mg/ml | | 3827 |
| | | Human albumin : 45 mg/ml Vancomycin hydrochloride : 5 mg/ml | | 3485 |
| | | Human albumin : 25 mg/ml Verapamil hydrochloride : 0.08 mg/ml | | 1057 |
| | | Human albumin : 200 mg/ml | | 3948 |


































Bibliographie

| | Type | Source |
|------|--------|---|
| 186 | Revue | Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022. |
| 198 | Revue | Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 1057 | Revue | Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 2108 | Revue | Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232. |
| 3485 | Revue | Huey-Ping Ng, Kwong-Fah Koh, Lai-San Tham. Vancomycin causes dangerous precipitation when infused with gelatin fluid. Anaesthesia 2000 ; 55, 10: 1039-1040. |
| 3490 | Revue | Elwell R.J, Spencer A.P, Barnes J.F, Wynn J.E, Jones C.E. Stability of furosemide in human albumin solution. Ann Pharmacotherapy 2002 ; 36: 423-426. |
| 3728 | Revue | Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291. |
| 3824 | Revue | Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98 |
| 3827 | Poster | Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015 |
| 3828 | Poster | Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015 |
| 3829 | Poster | So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015 |
| 3879 | Revue | Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332. |
| 3948 | Revue | Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424. |
| 3964 | Revue | Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33. |
| 3976 | Revue | Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218 |

| | | |
|------|-------|--|
| 4055 | Revue | Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4145 | Revue | Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4389 | Revue | Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213 |
| 4433 | Revue | Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485. |
| 4434 | Revue | Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170. |
| 4465 | Revue | Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148 |
| 4528 | Revue | Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61 |
| 4603 | Revue | Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4742 | Revue | Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255. |
| 4801 | Revue | Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1: |



Dictionnaire

| | |
|--|---|
|  Divers |  Injectable |
|  Noms commerciaux |  Stabilité en mélange |
|  Contenant |  Solvant |
|  Concentration |  Température |
|  Conservation |  Molécule |
|  Durée de stabilité |  Bibliographie |
|  Verre |  Aucun |
|  A l'abri de la lumière |  Heure |
|  Jour |  Compatibilités |
|  Incompatible |  Précipitation immédiate |
|  Chlorure de sodium 0,9% |  Compatible |
|  Turbidité immédiate |  NaCl 0,9% ou glucose 5% |
|  Instabilité de l'émulsion immédiate |  Nutrition parentérale (mélange ternaire) |
| RL Ringer lactate |  Glucose 5% |
|  Turbidité en 8 heures |  Nutrition parentérale (mélange binaire) |
|  Bibliographie |  Dictionnaire |